Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing
By: Colorado BioScience Association Date: 07/21/2022
Cerebral Therapeutics, a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today $40 million in Series C funding led by Lynx1 Capital Management with part...
Learn MoreWeekly Policy Update: Senate Prescription Drug Pricing Legislation
By: Colorado BioScience Association Date: 07/15/2022
Democrats in the U.S. Senate continue to negotiate an economic package that advances President Joe Biden’s key priorities. Prescription drug pricing legislation that would drastically alter the Medica...
Learn MoreSecurisyn Medical Announces Strategic Manufacturing and Distribution Partnership with SunMed Group Holdings
By: Colorado BioScience Association Date: 07/14/2022
Securisyn Medical LLC, (“Securisyn” or the “Company”), an emerging medical device company dedicated to enhancing ventilated patient safety and broader smooth tube and catheter securement, and SunMed G...
Learn MorePhilips Incorporates Biodesix Blood-based Proteomic Nodule Risk Assessment Testing into Lung Cancer Orchestrator to Advance Early Lung Cancer Diagnosis
By: Colorado BioScience Association Date: 07/01/2022
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has teamed up with Biodesix, Inc. (Colorado, U.S.) (Nasdaq: BDSX), a leading data-dri...
Learn MoreMorgridge Family Foundation gifts $3M to CSU Spur and College of Agricultural Sciences
By: Colorado BioScience Association Date: 06/07/2022
The Morgridge Family Foundation has imparted a transformational gift of $3 million to support the Colorado State University College of Agricultural Sciences and educational program...
Learn MoreBiodesix Announces Research Agreement with Top US Cancer Center
By: Colorado BioScience Association Date: 06/07/2022
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel minimal residual disease (MRD) te...
Learn MoreWatchmaker Genomics Raises $40M Series A Financing to Accelerate Growth and Expand Clinical Sequencing Product Offerings
By: Colorado BioScience Association Date: 06/02/2022
Watchmaker Genomics, a life sciences company specializing in the development of high-stringency applications focused on the reading, writing, and editing of DNA and RNA, today announced it had secured...
Learn MoreBrickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02
By: Colorado BioScience Association Date: 05/19/2022
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription...
Learn MoreAGC Biologics Invests in Viral Vector Suspension at New U.S. Campus
By: Colorado BioScience Association Date: 05/19/2022
AGC Biologics today announced it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Col., USA...
Learn MoreWeekly Policy Update: Legislative Session Comes to a Close This Week
By: Colorado BioScience Association Date: 05/09/2022
The legislative session is scheduled to end this Wednesday, May 11th. As we enter these final three days, the CBSA team continues to weigh in on key legislation and advocate on behalf of our life scie...
Learn More